Experience (1 year) of G-CSF biosimilars in PBSCT for lymphoma and myeloma patients
Authors:
- 26 September 2011
- journal article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 47 (6) , 874-876
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Delayed G‐CSF stimulation after PBSCT does not seem to modify the biological parameters of bone marrow recoveryAmerican Journal of Hematology, 2011
- Biosimilar agents in oncology/haematology: from approval to practiceEuropean Journal of Haematology, 2010
- Utilization study of filgrastim (Neutromax®) during autologous haematopoietic precursor transplantation for myeloma and lymphoma patientsTransfusion and Apheresis Science, 2009
- The challenge of biosimilarsAnnals of Oncology, 2007
- The protein science of biosimilarsNephrology Dialysis Transplantation, 2006
- 2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice GuidelineJournal of Clinical Oncology, 2006
- Cost effectiveness of day 5 G-CSF (Lenograstim®) administration after PBSC transplantation: results of a SFGM-TC randomised trialBone Marrow Transplantation, 2005
- Guidelines on the use of colony‐stimulating factors in haematological malignanciesBritish Journal of Haematology, 2003
- Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit.Journal of Clinical Oncology, 1997